Haemonetics Co. Expected to Post Q1 2025 Earnings of $0.94 Per Share (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Zacks Research lifted their Q1 2025 EPS estimates for shares of Haemonetics in a report issued on Thursday, March 28th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $0.94 per share for the quarter, up from their prior estimate of $0.93. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.08 EPS, FY2025 earnings at $4.12 EPS, Q1 2026 earnings at $1.19 EPS and FY2026 earnings at $4.77 EPS.

A number of other research analysts have also recently issued reports on the stock. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Finally, Barrington Research reissued an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a report on Tuesday, February 13th.

Haemonetics Trading Up 1.5 %

Shares of NYSE HAE opened at $85.35 on Friday. Haemonetics has a 1 year low of $70.74 and a 1 year high of $95.26. The stock has a market cap of $4.33 billion, a P/E ratio of 34.70, a price-to-earnings-growth ratio of 2.13 and a beta of 0.34. The firm has a 50-day moving average of $77.21 and a 200 day moving average of $83.30. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. During the same period last year, the company posted $0.85 EPS. Haemonetics’s revenue was up 10.1% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HAE. American Century Companies Inc. grew its position in Haemonetics by 163.5% during the first quarter. American Century Companies Inc. now owns 17,407 shares of the medical instruments supplier’s stock valued at $1,100,000 after buying an additional 10,802 shares during the period. PNC Financial Services Group Inc. grew its position in Haemonetics by 3.1% during the first quarter. PNC Financial Services Group Inc. now owns 12,802 shares of the medical instruments supplier’s stock valued at $809,000 after buying an additional 387 shares during the period. Bank of Montreal Can grew its position in Haemonetics by 300.3% during the first quarter. Bank of Montreal Can now owns 33,039 shares of the medical instruments supplier’s stock valued at $2,033,000 after buying an additional 24,785 shares during the period. Rhumbline Advisers grew its position in Haemonetics by 1.9% during the first quarter. Rhumbline Advisers now owns 148,770 shares of the medical instruments supplier’s stock valued at $9,405,000 after buying an additional 2,817 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Haemonetics by 10.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,732 shares of the medical instruments supplier’s stock valued at $1,184,000 after buying an additional 1,788 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.